Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Ischemic Stroke l: Introduction01:15

Ischemic Stroke l: Introduction

Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.
Stroke: Introduction and Types01:29

Stroke: Introduction and Types

A stroke is an acute neurological event caused by the sudden disruption of cerebral blood flow, leading to rapid loss of neuronal function. Neurons depend on continuous oxygen and glucose supply, so even brief interruptions can cause irreversible injury within minutes. Strokes are classified into ischemic and hemorrhagic types.Ischemic StrokeIschemic strokes are most common and occur due to arterial occlusion, depriving brain tissue of oxygen and nutrients. This leads to energy failure, ionic...
Ischemic Stroke ll: Pathophysiology01:15

Ischemic Stroke ll: Pathophysiology

An ischemic stroke occurs when a cerebral blood vessel becomes obstructed, most often by a thrombus or embolus, interrupting the delivery of oxygen and glucose to brain tissue. Because neurons rely on continuous aerobic metabolism, energy failure begins within minutes of reduced perfusion. The region receiving the least blood flow becomes the infarct core, an area of irreversible cellular death. Surrounding this core lies the penumbra, a zone of hypoperfused but still viable tissue that is...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of surrogate endpoints for survival outcomes using the surrogate package in R.

Computer methods and programs in biomedicine·2026
Same author

Integrating oral health screening into general practice: validation study of the Oral Health Screener.

Scientific reports·2026
Same author

Time-Scale Target Parameters and Two-Step Estimation in Longitudinal Trials for Progressive Diseases.

Statistics in medicine·2026
Same author

Handling Missing Data in Participants with Baseline but No Post-Baseline Data.

Pharmaceutical statistics·2026
Same author

A review of evidence supporting amyloid beta reduction as a surrogate endpoint in Alzheimer's disease.

The journal of prevention of Alzheimer's disease·2026
Same author

Predicting unplanned hospital revisits among community-dwelling older adults: a dynamic cohort study.

European journal of hospital pharmacy : science and practice·2025

Related Experiment Video

Updated: May 18, 2026

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
06:01

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

Secondary stroke prevention: misguided by guidelines?

Luk Vanstreels1, Geert Molenberghs, Jens-Uwe Voigt

  • 1University Hospitals of Leuven, Leuven, Belgium. luk.vanstreels@uzleuven.be

Acta Cardiologica
|September 25, 2012
PubMed
Summary
This summary is machine-generated.

Aspirin monotherapy remains the primary antiplatelet strategy for preventing recurrent non-cardioembolic ischemic stroke. Combination therapies like aspirin plus dipyridamole showed limited benefits and higher discontinuation rates.

More Related Videos

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

Related Experiment Videos

Last Updated: May 18, 2026

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
06:01

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

Area of Science:

  • Neurology
  • Cardiology
  • Pharmacology

Background:

  • Secondary prevention of non-cardioembolic ischemic stroke lacks a consensus antithrombotic strategy.
  • Existing clinical trials present conflicting evidence on optimal treatment.

Purpose of the Study:

  • To synthesize data from major trials on antithrombotic strategies for secondary stroke prevention.
  • To evaluate effectiveness, adverse events, compliance, and cost of various antiplatelet agents.

Main Methods:

  • Retrospective analysis of long-term secondary prevention trials (1996-2011).
  • Included treatments: aspirin, dipyridamole, clopidogrel, and their combinations.
  • Subgroup analyses were performed to interpret guideline discrepancies.

Main Results:

  • Aspirin plus dipyridamole showed a small, significant stroke recurrence reduction versus aspirin alone, but with higher discontinuation rates.
  • Clopidogrel demonstrated a minor significant reduction in stroke recurrence compared to aspirin.
  • Combination therapy with clopidogrel and aspirin did not offer significant benefits over monotherapy and increased adverse events.

Conclusions:

  • Aspirin monotherapy should remain the cornerstone antiplatelet agent for secondary prevention of non-cardioembolic ischemic stroke.
  • Despite guideline changes, evidence does not strongly support newer combination therapies over aspirin alone for this indication.